vTv Therapeutics (NASDAQ:VTVT) Shares Pass Above Fifty Day Moving Average - Should You Sell?

Key Points

• vTv Therapeutics' stock surpassed its 50-day moving average, reaching a trading high of $23.50, with a last traded price of $22.38.
• Analysts from HC Wainwright maintain a "buy" rating for vTv Therapeutics, setting a price target of $36.00, while the consensus target is $35.50.
• The company recently reported a loss of ($0.92) earnings per share, missing the consensus estimate by $0.07.

vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report)'s stock price crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $16.73 and traded as high as $23.50. vTv Therapeutics shares last traded at $22.38, with a volume of 25,633 shares.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a "buy" rating and set a $36.00 price objective on shares of vTv Therapeutics in a research report on Wednesday, August 13th. Two analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $35.50.

vTv Therapeutics Trading Up 4.8%

The firm has a 50 day moving average price of $16.73 and a 200-day moving average price of $17.41. The firm has a market cap of $71.39 million, a PE ratio of -7.17 and a beta of 0.64.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The biotechnology company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.07).

Institutional Investors Weigh In On vTv Therapeutics

An institutional investor recently bought a new position in vTv Therapeutics stock. Connective Capital Management LLC bought a new position in shares of vTv Therapeutics Inc. (NASDAQ:VTVT - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 9,377 shares of the biotechnology company's stock, valued at approximately $162,000. Connective Capital Management LLC owned about 0.29% of vTv Therapeutics as of its most recent SEC filing. Institutional investors own 17.51% of the company's stock.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.